Masatomo Kato Selected Research

WEB 2086 (apafant)

8/2004	Apafant, a potent platelet-activating factor antagonist, blocks eosinophil activation and is effective in the chronic phase of experimental allergic conjunctivitis in guinea pigs.
8/2003	The role of platelet activating factor and the efficacy of apafant ophthalmic solution in experimental allergic conjunctivitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masatomo Kato Research Topics

Disease

3	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 08/2011 - 08/2003
2	Conjunctivitis 08/2011 - 08/2003
1	Blister (Bulla) 01/2021
1	Edema (Dropsy) 08/2011
1	Eye Diseases (Eye Disease) 08/2011
1	Hypersensitivity (Allergy) 08/2004
1	Anaphylaxis (Anaphylactic Shock) 08/2003

Drug/Important Bio-Agent (IBA)

3	Ophthalmic Solutions (Eye Drops)IBA 08/2011 - 08/2003
2	Platelet Activating FactorIBA 08/2004 - 08/2003
2	WEB 2086 (apafant)IBA 08/2004 - 08/2003
1	betamethasone sodium phosphate FDA LinkGeneric 08/2011
1	ZK 216348IBA 08/2011
1	CarrageenanIBA 08/2011
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 08/2011
1	Anti-Allergic Agents (Antiallergic Agents)IBA 08/2011
1	SolutionsIBA 08/2004
1	OvalbuminIBA 08/2004
1	AntigensIBA 08/2003

Therapy/Procedure

1	Trabeculectomy (Trabeculoplasty) 01/2021
1	Ophthalmic Administration 08/2003